Acral persistent papular mucinosis
Other namesAPPM
SpecialtyDermatology
Differential diagnosisDiscrete papular lichen myxoedematosus, Cutaneous papular mucinosis of infancy, Nodular lichen myxoedematosus.[1]
TreatmentTopical and intralesional corticosteroids.[1]
FrequencyAround 40 cases as of 2021.[2]

Acral persistent papular mucinosis (APPM) is a rare form of lichen myxedematosus. It is characterized by small papules on the backs of the hands, wrists, and extensor aspects of the distal forearms, with no further clinical or laboratory indications. Lesions tend to persist and may grow in number gradually. Because there are no symptoms, treatment is rarely required.[3]

Signs and symptoms

Acral persistent papular mucinosis is a chronic idiopathic cutaneous mucinosis with the following characteristics:[2]

  1. Papules, nodules, and/or plaques of lichenoid origin
  2. Mucin deposition in conjunction with varying degrees of dermal fibrosis and fibroblast proliferation
  3. The absence of thyroid disease.

Causes

The cause of Acral persistent papular mucinosis is unknown, but genetic and environmental factors appear to play a role, as familial cases have been reported.[4] TNF-α and TGF-β have been proposed to stimulate glycosaminoglycan synthesis, however, the exact triggers are unknown.[2]

Diagnosis

Histologically, hematoxylin-eosin and Alcian blue staining show mucin accumulation in the upper reticular dermis, as well as collagen fiber separation due to hyaluronic acid deposition. Mucin accumulation may result in epidermis thinning.[3] Fibroblast proliferation is sometimes increased.[5]

Differential diagnosis

In addition to various forms of mucinosis, the differential diagnosis includes a range of papular diseases such as granuloma annulare, molluscum contagiosum, acrokeratoelastoidosis, lichen amyloidosis, lichen planus, and eruptive collagenoma.[2] The exact positions of the lesions and findings on histopathology using alcian blue stain aid in the diagnosis. APPM should be distinguished from the discrete papular form of lichen myxedematosus (DPLM), which is considered another subtype of lichen myxedematosus.[6] Papules in DPLM can affect any part of the body, typically in an asymmetrical pattern. Histologically, DPLM has more diffuse and interstitial mucin deposition in the upper to mid dermis, at times with increased fibroblasts.[2]

One may also take into consideration self-healing juvenile cutaneous mucinosis (SHJCM).[2] In contrast, SHJCM is typified by an acute popular eruption that can combine to form linear infiltrated plaques on the face, neck, scalp, abdomen, and/or thighs. In addition, SHJCM is linked to fever, arthralgia, weakness, and tenderness in the muscles in children. Mucinous subcutaneous nodules on the face, sometimes associated with periorbital swelling, and on the periarticular areas are prominent features. A papule exhibits mucin dermal deposition with a perivascular inflammatory infiltrate, whereas nodules exhibit fibroblastic reactive proliferation that involves the subcutaneous fat, akin to nodular or proliferative fasciitis, with mucin deposited throughout the dermis and subcutis. Usually, spontaneous resolution happens in a few weeks to several months.[7]

Finally, the most important differential diagnosis is scleromyxedema. Localized lichen myxedematosus and scleromyxedema were once thought to be the same disease, but they are actually part of a spectrum in the context of primary cutaneous mucinoses. Clinical, histologic, and laboratory findings can help differentiate between the two disorders.[2] Clinically, scleromyxedema tends to be diffuse and sclerodermoid, with systemic manifestations similar to scleroderma. Scleromyxedema's classic histopathologic findings are a microscopic triad of mucin deposition, fibroblast proliferation, and fibrosis, or, in rare cases, an interstitial granuloma annulare-like pattern.[8] Scleromyxedema, unlike APPM, occurs in association with monoclonal gammopathy and can have a wide range of systemic manifestations, including neurologic, rheumatologic, pulmonary, and cardiovascular indications.[9]

Treatment

There are few therapeutic options however, no specific treatment exists. Treatment is not always necessary, and APPM is mostly a cosmetic issue.[2] Treatment with topical or intralesional steroids and topical calcineurin inhibitors has been reported anecdotally.[10] Other interventions with variable results include dermabrasion, electrosurgery,[11] carbon dioxide laser, and erbium-YAG (yttrium aluminum garnet) laser.[12] The latter has the potential to leave scars. The course is benign, though spontaneous resolution is rare. Often, the number of papules increases gradually over time.[2]

Epidemiology

Acral persistent papular mucinosis has a strong female predominance. the mean age at onset is 48 years and reported patients have ranged from 14 years old to 84. The mean duration of the disease 5.6 years, ranging from 6 months to years. The majority of cases have been reported in Europe, particularly in Spain and Italy, but there have also been cases reported in North and South America and Southeast Asia. It is unknown why the majority of cases come from Europe, but it could be that the disease is more commonly recognized in Western countries.[2]

History

Rongioletti et al. described acral persistent papular mucinosis in 1986 as one of the five types of lichen myxedematosus.[3]

See also

References

  1. 1 2 "Acral persistent papular mucinosis". DermNet. Retrieved November 16, 2023.
  2. 1 2 3 4 5 6 7 8 9 10 Rongioletti, Franco; Ferreli, Caterina; Atzori, Laura (2021). "Acral persistent papular mucinosis". Clinics in Dermatology. Elsevier BV. 39 (2): 211–214. doi:10.1016/j.clindermatol.2020.10.001. ISSN 0738-081X. PMID 34272012. S2CID 263488467. Retrieved November 15, 2023.
  3. 1 2 3 Gómez Sánchez, María Encarnación; Manueles Marcos, Fernando de; Martínez Martínez, Maria Luisa; Vera Berón, Roberto; Azaña Défez, Jose Manuel (2016). "Acral papular mucinosis: a new case of this rare entity". Anais Brasileiros de Dermatologia. FapUNIFESP (SciELO). 91 (5 suppl 1): 111–113. doi:10.1590/abd1806-4841.20164804. ISSN 0365-0596. PMC 5325012. PMID 28300913.
  4. ↑ MENNI, S.; CAVICCHINI, S.; BREZZI, A.; GIANOTTI, R.; CAPUTO, R. (1995). "Acral persistent papular mucinosis in two sisters". Clinical and Experimental Dermatology. Oxford University Press (OUP). 20 (5): 431–433. doi:10.1111/j.1365-2230.1995.tb01366.x. ISSN 0307-6938. PMID 8593726. S2CID 44342763. Retrieved November 15, 2023.
  5. ↑ Harris, Jocelyn E.; Purcell, Stephen M.; Griffin, Thomas D. (2004). "Acral persistent papular mucinosis". Journal of the American Academy of Dermatology. Elsevier BV. 51 (6): 982–988. doi:10.1016/j.jaad.2004.07.002. ISSN 0190-9622. PMID 15583597. Retrieved November 15, 2023.
  6. ↑ Fosko, Scott W.; Perez, Maritza I.; Jack Longley, B. (1992). "Acral persistent papular mucinosis". Journal of the American Academy of Dermatology. Elsevier BV. 27 (6): 1026–1029. doi:10.1016/s0190-9622(08)80277-0. ISSN 0190-9622. PMID 1479089. Retrieved November 15, 2023.
  7. ↑ Luchsinger, Isabelle; Coulombe, Jérôme; Rongioletti, Franco; Haspeslagh, Marc; Dompmartin, Anne; Melki, Isabelle; Dagher, Rawane; Bader-Meunier, Brigitte; Fraitag, Sylvie; Bodemer, Christine (2018). "Self-healing juvenile cutaneous mucinosis: Clinical and histopathologic findings of 9 patients". Journal of the American Academy of Dermatology. Elsevier BV. 78 (6): 1164–1170. doi:10.1016/j.jaad.2017.10.023. ISSN 0190-9622. PMID 29066274. S2CID 21658209. Retrieved November 15, 2023.
  8. ↑ Cokonis Georgakis, Clara-Dina; Falasca, Gerald; Georgakis, Alexander; Heymann, Warren R. (2006). "Scleromyxedema". Clinics in Dermatology. Elsevier BV. 24 (6): 493–497. doi:10.1016/j.clindermatol.2006.07.011. ISSN 0738-081X. PMID 17113967. Retrieved November 15, 2023.
  9. ↑ Rongioletti, Franco; Merlo, Giulia; Cinotti, Elisa; Fausti, Valentina; Cozzani, Emanuele; Cribier, Bernard; Metze, Dieter; Calonje, Eduardo; Kanitakis, Jean; Kempf, Werner; Stefanato, Catherine M.; Marinho, Eduardo; Parodi, Aurora (2013). "Scleromyxedema: A multicenter study of characteristics, comorbidities, course, and therapy in 30 patients". Journal of the American Academy of Dermatology. Elsevier BV. 69 (1): 66–72. doi:10.1016/j.jaad.2013.01.007. ISSN 0190-9622. PMID 23453242. S2CID 205508172. Retrieved November 15, 2023.
  10. ↑ Iglesias-Plaza, Ana; Melé-Ninot, Gemma; Pérez-Muñoz, Noelia; Salleras-Redonnet, Montse (2018). "Acral persistent papular mucinosis with pruritic skin lesions". Anais Brasileiros de Dermatologia. FapUNIFESP (SciELO). 93 (5): 769–770. doi:10.1590/abd1806-4841.20187878. ISSN 1806-4841. PMC 6106683. PMID 30156641.
  11. ↑ Jorge, Flávia André; Cortez, Tatiana Mimura; Mendes, Fabiana Guadalini; Marques, Mariângela Esther Alencar; Miot, Hélio Amante (2011). "Treatment of Acral Persistent Papular Mucinosis with Electrocoagulation". Journal of Cutaneous Medicine and Surgery. SAGE Publications. 15 (4): 227–229. doi:10.2310/7750.2011.10030. ISSN 1203-4754. PMID 21781629. S2CID 73387123. Retrieved November 15, 2023.
  12. ↑ Graves, Michael S.; Lloyd, Amanda A.; Ross, Edward V. (May 7, 2015). "Treatment of acral persistent papular mucinosis using an Erbium-YAG laser". Lasers in Surgery and Medicine. Wiley. 47 (6): 467–468. doi:10.1002/lsm.22368. ISSN 0196-8092. PMID 25952726. S2CID 43572880. Retrieved November 15, 2023.

Further reading

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.